Copan strengthens its operations in the Americas with a millionaire investment
PR89959
BRESCIA, Italy, June 8, 2021 /PRNewswire=KYODO JBN/ --
Copan announces a $78 million investment to expand its Puerto Rican production
site. The project – partially financed by Puerto Rico's Government – will bring
Copan production and distribution capacity closer to the American market,
strengthening the company's presence in the US and the rest of the Americas.
Copan Group announced a millionaire investment to expand its production
capacity in Aguadilla, Puerto Rico, which joined the main Italian production
site three years ago. The operation has a total value of over $ 78 million: $9
million will be allocated to purchase and maintain new machinery, while the
rest will be invested to increase the number of employees from 100 to 352.
"The establishment of our company in Puerto Rico has proven to provide
favorable conditions for the expansion and growth of our business globally,"
declared Stefania Triva, Copan Group's President. "With this investment, we aim
to strengthen our presence in the US market: through a hub & spoke distribution
strategy, we'll be able to offer a competitive service with unprecedented
efficiency and rapidity throughout all the American territory," she continues.
Puerto Rico's Economic Development and Commerce Department supported the
operation by approving $23 million of incentives, seeing in the project – which
brings Copan's technological know-how, quality, and work welfare attitude
across the ocean – an excellent opportunity for the whole US. According to
Puerto Rican Governor Pedro Pierluisi, "manufacturing companies as Copan
represent an important component of the economy, as they contribute to creating
and retaining jobs. We are proud of the talent that exists in Puerto Rico, and
we are confident in the continued success and commitment of Copan Industries to
the Island."
Copan's recent activity has been fervent in the US, with investments in Puerto
Rico, California, and the successful clearance of products finally available in
the US – as the eNAT (R) nucleic acid storage and stabilization device
FDA-cleared at the end of 2020. This project fits Copan's current strategy to
bring production sites closer to the end markets, streamlining logistics and
enabling an efficient and prompt service everywhere globally.
About Copan
Copan is dedicated to developing high-quality and cutting-edge sample
collection products for infectious diseases, human genomics, environmental and
forensic applications, along with automated workflow solutions. Our ideas drove
40 years of progress in the field of preanalytics, resulting in the development
of meaningful products tailored to fit any need. Among them, our patented
FLOQSwabs (R) reinvented completely sample collection and transport, while the
WASPLab (R) automation ecosystem revolutionized laboratory workflow. Today,
Copan is still eager to continue this innovation, providing quality products,
customized services, and prime solutions to improve patients' health.
Photo - https://mma.prnewswire.com/media/1527451/Copan_Puerto_Rico.jpg
Logo - https://mma.prnewswire.com/media/1484615/CopanHD_Logo.jpg
Source: Copan Italia SpA
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。